NZ730816A - Quinoline carboxamides for use in the treatment of multiple myeloma - Google Patents
Quinoline carboxamides for use in the treatment of multiple myelomaInfo
- Publication number
- NZ730816A NZ730816A NZ730816A NZ73081615A NZ730816A NZ 730816 A NZ730816 A NZ 730816A NZ 730816 A NZ730816 A NZ 730816A NZ 73081615 A NZ73081615 A NZ 73081615A NZ 730816 A NZ730816 A NZ 730816A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- multiple myeloma
- quinoline carboxamides
- carboxamides
- quinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185892 | 2014-09-23 | ||
| PCT/EP2015/071391 WO2016042112A1 (en) | 2014-09-23 | 2015-09-18 | Quinoline carboxamides for use in the treatment of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ730816A true NZ730816A (en) | 2022-01-28 |
Family
ID=51660309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ730816A NZ730816A (en) | 2014-09-23 | 2015-09-18 | Quinoline carboxamides for use in the treatment of multiple myeloma |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956212B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3041472B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6647287B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102533033B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107108510B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015316824B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2961978C (cg-RX-API-DMAC7.html) |
| EA (1) | EA030948B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2631194T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL251043B (cg-RX-API-DMAC7.html) |
| MX (1) | MX366837B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ730816A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3041472T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016042112A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201702377B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6647287B2 (ja) * | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| IL295780A (en) | 2020-03-03 | 2022-10-01 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| JP7747732B2 (ja) | 2020-07-23 | 2025-10-01 | イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム | 骨髄増殖性腫瘍における新規治療用標的としてのｓ１００タンパク質 |
| US20240091215A1 (en) | 2021-01-18 | 2024-03-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| KR20240012436A (ko) | 2021-05-25 | 2024-01-29 | 액티브 바이오테크 에이비 | 복수의 타스퀴니모드 입자 및 그 용도 |
| CA3221689A1 (en) | 2021-07-02 | 2023-01-05 | Hans Wannman | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| CN100390148C (zh) * | 1999-10-25 | 2008-05-28 | 活跃生物技术有限公司 | 用于治疗恶性肿瘤的药物 |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| KR20130043104A (ko) * | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| CA2802006C (en) | 2010-07-09 | 2018-09-25 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| AU2011291599B2 (en) * | 2010-08-18 | 2015-09-10 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
| WO2012034543A1 (es) | 2010-09-13 | 2012-03-22 | Universidad De Costa Rica | Conector estructural para bambú |
| FR2967353B1 (fr) * | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| JP6647287B2 (ja) * | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
-
2015
- 2015-09-18 JP JP2017513751A patent/JP6647287B2/ja active Active
- 2015-09-18 ES ES15763622.6T patent/ES2631194T3/es active Active
- 2015-09-18 AU AU2015316824A patent/AU2015316824B2/en active Active
- 2015-09-18 US US15/510,728 patent/US9956212B2/en active Active
- 2015-09-18 PL PL15763622T patent/PL3041472T3/pl unknown
- 2015-09-18 CA CA2961978A patent/CA2961978C/en active Active
- 2015-09-18 MX MX2017003294A patent/MX366837B/es active IP Right Grant
- 2015-09-18 WO PCT/EP2015/071391 patent/WO2016042112A1/en not_active Ceased
- 2015-09-18 EP EP15763622.6A patent/EP3041472B1/en active Active
- 2015-09-18 CN CN201580051397.XA patent/CN107108510B/zh active Active
- 2015-09-18 EA EA201790687A patent/EA030948B1/ru not_active IP Right Cessation
- 2015-09-18 NZ NZ730816A patent/NZ730816A/en unknown
- 2015-09-18 KR KR1020177010510A patent/KR102533033B1/ko active Active
-
2017
- 2017-03-09 IL IL251043A patent/IL251043B/en active IP Right Grant
- 2017-04-04 ZA ZA2017/02377A patent/ZA201702377B/en unknown
-
2018
- 2018-04-06 US US15/947,279 patent/US10314836B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170052691A (ko) | 2017-05-12 |
| JP6647287B2 (ja) | 2020-02-14 |
| CA2961978C (en) | 2023-03-14 |
| JP2017528473A (ja) | 2017-09-28 |
| IL251043B (en) | 2020-02-27 |
| AU2015316824B2 (en) | 2020-10-29 |
| CN107108510B (zh) | 2020-10-23 |
| MX366837B (es) | 2019-07-26 |
| BR112017004947A2 (pt) | 2017-12-05 |
| CA2961978A1 (en) | 2016-03-24 |
| ZA201702377B (en) | 2018-08-29 |
| CN107108510A (zh) | 2017-08-29 |
| PL3041472T3 (pl) | 2017-08-31 |
| US10314836B2 (en) | 2019-06-11 |
| WO2016042112A1 (en) | 2016-03-24 |
| EP3041472B1 (en) | 2017-02-01 |
| ES2631194T3 (es) | 2017-08-29 |
| EA201790687A1 (ru) | 2017-08-31 |
| IL251043A0 (en) | 2017-04-30 |
| AU2015316824A1 (en) | 2017-04-27 |
| US20180228794A1 (en) | 2018-08-16 |
| US9956212B2 (en) | 2018-05-01 |
| MX2017003294A (es) | 2017-06-23 |
| EP3041472A1 (en) | 2016-07-13 |
| US20170273967A1 (en) | 2017-09-28 |
| KR102533033B1 (ko) | 2023-05-15 |
| EA030948B1 (ru) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| ZA201701299B (en) | Glycosidase inhibitors | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| TN2015000519A1 (en) | Small molecule inhibitors of fibrosis | |
| PH12015501588B1 (en) | Compounds and methods for treating bacterial infections | |
| AU2015352440B2 (en) | Compounds | |
| TN2016000535A1 (en) | Ppar compounds for use in the treatment of fibrotic diseases. | |
| MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| IL250038A0 (en) | 4,5 - dehydroisoxazole derivatives used as nampt inhibitors | |
| MX2015008829A (es) | Momelotinib deuterado. | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| SA517381678B1 (ar) | مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي | |
| NZ732704A (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| SMT201800378T1 (it) | Composti di 3,4-diammino-6-cloropirazina-2-carbossammide per il trattamento di patologie enac-mediate | |
| MX2018002193A (es) | Metodo de uso de quinoxalinilo-piperazinamida. | |
| PH12016502466A1 (en) | Ppar compounds for use in the treatment of fibrotic diseases | |
| TH104715B (th) | สารประกอบและวิธีการสำหรับการรักษาการติดเชื้อแบคทีเรีย | |
| UA91886U (uk) | 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE Effective date: 20220827 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2024 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20230822 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2025 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20240821 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 SEP 2026 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20250820 |